Submit Deal

Announced

19 Aug 2022

Completed

19 Aug 2022

Esco Lifesciences completed the spin-off of Esco Aster.

Synopsis

Esco Lifesciences, a life science company, completed the spin-off of Esco Aster, a vertically-integrated contract research organization. Financial terms were not disclosed.

Principals

target

Esco Aster

bidder

Institutional Investors

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Vendor Team (5)

beiming liu

Associate at Davis Polk & Wardwell

Lawyer

vendor

Deals

£ 4.26 B

Total Value

xq lin

Chairman and CEO at ESCO LIFESCIENCES GROUP

Manager

vendor

Deals

£ 141 M

Total Value

michael zhuoran xu

Associate at Davis Polk & Wardwell

Lawyer

vendor

Deals

£ 6.30 B

Total Value

yang chu

Partner at Davis Polk & Wardwell

Lawyer

vendor

Deals

£ 3.68 B

Total Value

howard zhang

Partner at Davis Polk & Wardwell

Lawyer

vendor

Deals

£ 20.55 B

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy